ERBB2-KD fusions occurred more commonly in gastroesophageal junction cancer (3.12%; 3/96), urothelial carcinoma (1.72%; 1/58), breast cancer (1.42%; 6/422), and gastric cancer (0.83%; 12/1,437) (Figures 2C, D and Table 4). Here, ERBB2 is linked to urothelial carcinoma.